No Data
Hong Kong Stock Concept Tracking | It is rumored that the World Health Organization plans to include weight loss drugs in the essential directory, accelerating the development progress of weight loss drugs (with related concept stocks).
Is this the first time weight loss drugs are included in the essential medicines list? The World Health Organization responded that the relevant plan is being formulated and is expected to be released as early as August.
Express News | Ascletis Announces Oral and Poster Presentations on Asc47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32Nd European Congress on Obesity
ASCLETIS-B (01672.HK): Will present the research results of the fat-targeting and weight-loss without muscle loss obesity candidate drug ASC47 in both oral and poster formats at the 32nd European Obesity Conference.
On May 6, Gelonghui announced that ASCLETIS-B (01672.HK) will report early research on the obesity candidate drug ASC47, which targets fat and promotes weight loss without reducing muscle, in both oral and poster presentations at the 32nd European Congress on Obesity (ECO 2025) held in Malaga, Spain. According to the disclosure, ASC47 is a thyroid hormone receptor beta (THRβ) selective small molecule agonist developed by ASCLETIS with a unique profile, capable of targeting fat and thus delivering dosage in adipose tissue.
ASCLETIS-B: Annual Report 2024
Hong Kong Stock Movement | ASCLETIS-B (01672) rose nearly 10% in the morning session as the research on obesity treatment drugs received positive top-line results and has submitted a Phase IIa research proposal to the FDA.
ASCLETIS-B (01672) rose nearly 10% in morning trading, as of the time of writing, it has increased by 5.13%, priced at 6.76 Hong Kong dollars, with a trading volume of 33.9117 million Hong Kong dollars.
Ascletis Pharma's Phase 1B Trial for Obesity Tablets Showed Favorable Safety Results
Anivid : over priced...